Shares of 180 Life Sciences Corp (ATNF) plunged 30% in pre-market trading on Thursday following the company's announcement of a significant stock offering. The biotechnology firm entered into a sales agreement that could potentially dilute existing shareholders' stakes, triggering a sharp sell-off.

According to a SEC filing, 180 Life Sciences has established a sales agreement with Clear Street LLC, allowing the company to offer and sell up to $500 million worth of its common stock. The shares may be sold through negotiated transactions or as "at the market offerings," with Clear Street LLC set to receive up to 3.0% of the gross sales price per share as compensation.

While the company has not specified the total number of shares to be offered or their price, the magnitude of the potential offering relative to 180 Life Sciences' market capitalization has spooked investors. Such large offerings are often viewed negatively by the market as they can significantly dilute the value of existing shares. The move suggests that the company is seeking substantial capital, possibly for research and development or to strengthen its financial position, but at the cost of shareholder value in the short term.